miR-221-5p and miR-186-5p Are the Critical Bladder Cancer Derived Exosomal miRNAs in Natural Killer Cell Dysfunction

Bladder cancer (BC) is the tenth most commonly diagnosed cancer worldwide, and its carcinogenesis mechanism has not been fully elucidated. BC is able to induce natural killer (NK) cell dysfunction and escape immune surveillance. The present study found that exosomes derived from the urinary bladder cancer cell line (T24 cell) contribute in generating NK cell dysfunction by impairing viability, and inhibiting the cytotoxicity of the NK cell on target cells. Meanwhile, T24 cell-derived exosomes inhibited the expression of the important functional receptors NKG2D, NKp30, and CD226 on NK cells as well as the secretion of perforin and granzyme-B. The critical miRNAs with high expression in T24 cell-derived exosomes were identified using high-throughput sequencing. Furthermore, following dual-luciferase reporter assay and transfection experiments, miR-221-5p and miR-186-5p were confirmed as interfering with the stability of the mRNAs of DAP10, CD96, and the perforin gene in NK cells and may be potential targets used in the therapy for BC.

[1]  S. Andò,et al.  A novel phage display based platform for exosome diversity characterization. , 2022, Nanoscale.

[2]  J. Olefsky,et al.  Exosomes as mediators of intercellular crosstalk in metabolism. , 2021, Cell metabolism.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  Ting Huyan,et al.  Extracellular Vesicles – Advanced Nanocarriers in Cancer Therapy: Progress and Achievements , 2020, International journal of nanomedicine.

[5]  Hong Ma,et al.  MiR‐221‐5p is involved in the regulation of inflammatory responses in acute gouty arthritis by targeting IL‐1β , 2020, International journal of rheumatic diseases.

[6]  Mengzhao Zhang,et al.  The role of exosomal miR‐375‐3p: A potential suppressor in bladder cancer via the Wnt/β‐catenin pathway , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  Annelisa M Cornel,et al.  MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy , 2020, Cancers.

[8]  W. Olejarz,et al.  Tumor-Derived Exosomes in Immunosuppression and Immunotherapy , 2020, Journal of immunology research.

[9]  Menglin Jiang,et al.  Promotion of miR-221-5p on the Sensitivity of Gastric Cancer Cells to Cisplatin and Its Effects on Cell Proliferation and Apoptosis by Regulating DDR1 , 2020, OncoTargets and therapy.

[10]  Z. Chen,et al.  miR-221-5p acts as an oncogene and predicts worse survival in patients of renal cell cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  N. Cacalano,et al.  Exosomes: Versatile Nano Mediators of Immune Regulation , 2019, Cancers.

[12]  Ting Huyan,et al.  MicroRNAs: Key Players in Bladder Cancer , 2019, Molecular Diagnosis & Therapy.

[13]  M. Spahn,et al.  miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo , 2019, BMC Cancer.

[14]  S. French,et al.  miR-186-5p promotes cell growth, migration and invasion of lung adenocarcinoma by targeting PTEN. , 2019, Experimental and molecular pathology.

[15]  X. Liu,et al.  miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs). , 2019, Neoplasma.

[16]  Liang Wang,et al.  MicroRNA-186-5p represses neuroblastoma cell growth via downregulation of Eg5. , 2019, American journal of translational research.

[17]  Zheng Xu,et al.  miR-186-5p Functions as a Tumor Suppressor in Human Osteosarcoma by Targeting FOXK1. , 2019, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology.

[18]  J. Ge,et al.  The functional potency of natural killer cells in response to IL‐2/IL‐15/IL‐21 stimulation is limited by a concurrent upregulation of Tim‐3 in bladder cancer , 2018, Experimental cell research.

[19]  Si-ying Zhou,et al.  Exosome: a novel mediator in drug resistance of cancer cells. , 2018, Epigenomics.

[20]  John A. Taylor,et al.  Metabolic changes in bladder cancer. , 2018, Urologic oncology.

[21]  Jianhua Ruan,et al.  Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer , 2018, Oncotarget.

[22]  Wei Zhu,et al.  miR-221-5p enhances cell proliferation and metastasis through post-transcriptional regulation of SOCS1 in human prostate cancer , 2018, BMC Urology.

[23]  L. Xia,et al.  MiR-186-5p upregulation inhibits proliferation, metastasis and epithelial-to-mesenchymal transition of colorectal cancer cell by targeting ZEB1. , 2018, Archives of biochemistry and biophysics.

[24]  Junling Shi,et al.  Bifacial effects of engineering tumour cell‐derived exosomes on human natural killer cells , 2017, Experimental cell research.

[25]  Raghu Kalluri,et al.  Exosomes Facilitate Therapeutic Targeting of Oncogenic Kras in Pancreatic Cancer , 2017, Nature.

[26]  Yang Xia,et al.  Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma patients through the exosomal pathway , 2017, Oncotarget.

[27]  T. Stankovic,et al.  NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma , 2016, Oncotarget.

[28]  E. N. Nolte-‘t Hoen,et al.  Extracellular vesicles and viruses: Are they close relatives? , 2016, Proceedings of the National Academy of Sciences.

[29]  Steven M Jay,et al.  Exogenous DNA Loading into Extracellular Vesicles via Electroporation is Size-Dependent and Enables Limited Gene Delivery. , 2015, Molecular pharmaceutics.

[30]  D. Iliopoulos,et al.  Identification of a Novel Substance P–Neurokinin-1 Receptor MicroRNA-221-5p Inflammatory Network in Human Colonic Epithelial Cells , 2015, Cellular and molecular gastroenterology and hepatology.

[31]  E. Oltra Relevance of Splicing on Tumor-Released Exosome Landscape: Implications in Cancer Therapeutics , 2014, Front. Endocrinol..

[32]  Clotilde Théry,et al.  Biogenesis and secretion of exosomes. , 2014, Current opinion in cell biology.

[33]  G. Berchem,et al.  The Critical Role of the Tumor Microenvironment in Shaping Natural Killer Cell-Mediated Anti-Tumor Immunity , 2013, Front. Immunol..

[34]  Y. Miao,et al.  Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer , 2013, Journal of Translational Medicine.

[35]  Ting Huyan,et al.  Effects of simulated microgravity on primary human NK cells. , 2013, Astrobiology.

[36]  J. Akers,et al.  Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies , 2013, Journal of Neuro-Oncology.

[37]  T. Whiteside Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). , 2013, Biochemical Society transactions.

[38]  B. Ursø,et al.  Cytotoxicity of CD56bright NK Cells towards Autologous Activated CD4+ T Cells Is Mediated through NKG2D, LFA-1 and TRAIL and Dampened via CD94/NKG2A , 2012, PloS one.

[39]  O. Mandelboim,et al.  CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells , 2011, The Journal of experimental medicine.

[40]  P. Altevogt,et al.  Body fluid derived exosomes as a novel template for clinical diagnostics , 2011, Journal of Translational Medicine.

[41]  T. Whiteside,et al.  Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. , 2011, Bulletin du cancer.

[42]  G. Ball,et al.  NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting , 2009, Clinical Cancer Research.

[43]  K. Yamaguchi,et al.  Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis , 2009, Cancer Immunology, Immunotherapy.

[44]  M. Mason,et al.  Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression1 , 2008, The Journal of Immunology.

[45]  M. Weller,et al.  TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells , 2006 .

[46]  Aled Clayton,et al.  Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids , 2006, Current protocols in cell biology.

[47]  M. Weller,et al.  TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. , 2006, Brain : a journal of neurology.

[48]  D. Taylor,et al.  Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects , 2005, British Journal of Cancer.

[49]  N. Minato,et al.  Analysis of natural killer activity and natural killer cell subsets in patients with bladder cancer , 2005, Cancer Immunology, Immunotherapy.

[50]  J. Zeuthen,et al.  Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: Decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells , 1990, Journal of Clinical Immunology.

[51]  S. Ferrone,et al.  Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. , 2002, Cancer research.

[52]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[53]  S. Natsugoe,et al.  Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. , 2000, Cancer letters.

[54]  M. A. Sáez,et al.  The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma , 1997, Cancer.

[55]  M. Álvarez-Mon,et al.  Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder. , 1990, The Journal of urology.